Seek Returns

A vs. BIIB: Agilent vs. Biogen Stock Comparison

How do Agilent (A) and Biogen (BIIB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Biogen (BIIB) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while BIIB is classified in Biotechnology.

Company profile comparison for Agilent (A) and Biogen (BIIB)
Profile ItemABIIB
NameAgileThought, Inc. Class A Common StockBiogen Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization49.28 billion USD36.71 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateNovember 18, 1999September 17, 1991
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

A
BIIB
GSPC
Loading price history…
Agilent (A) vs. Biogen (BIIB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and Biogen (BIIB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and Biogen (BIIB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
Total Return (1Y)22.92%65.44%
Total Return (3Y, Annualized)19.33%4.62%
Total Return (5Y, Annualized)3.03%-0.96%

Risk Profile

Drawdown History

A
BIIB
GSPC
Loading price history…
Agilent (A) vs. Biogen (BIIB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and Biogen (BIIB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
Volatility (1Y, Annualized)33.10%34.58%
Beta (5Y)1.220.08
Max Drawdown (5Y)-38.09%-64.35%
Avg. Volume (3M)2.25M1.05M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and BIIB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
Sharpe Ratio (1Y)0.561.77
Sortino Ratio (1Y)0.962.77

Profitability

ROE (TTM)

Agilent (A) at 20.97% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max
109.18%
Q3
6.23%
BIIB
1.87%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Agilent (A) at 19.53% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max
18.05%
Q3
4.78%
BIIB
3.38%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Biogen (BIIB) at 24.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max
83.12%
BIIB
24.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
ROE (TTM)20.97%1.87%
ROA (TTM)8.63%4.94%
Net Margin (TTM)19.53%3.38%
Operating Margin (TTM)25.56%24.12%
Gross Margin (TTM)53.65%75.77%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and Biogen (BIIB) at 2.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and Biogen (BIIB) at -21.38% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
Revenue Growth (YoY)6.73%2.22%
Revenue Growth (3Y CAGR)0.48%-0.94%
EPS Growth (YoY)3.16%-21.38%
EPS Growth (3Y CAGR)3.02%-25.04%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and Biogen (BIIB) at 1.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BIIB
1.95
Min
0.10
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Agilent (A) at 0.56 and Biogen (BIIB) at 0.41 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max
1.42
Q3
0.65
BIIB
0.41
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
Current Ratio (MRQ)2.051.95
Debt / Equity (MRQ)0.560.41
Net Debt / EBITDA1.151.97

Dividends

Dividend Yield (TTM)

Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Biogen (BIIB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
Dividend Yield (TTM)0.59%0.00%
Dividend Payout Ratio (TTM)19.98%0.00%

Valuation

P/E Ratio (TTM)

Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB
107.51
Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Biogen (BIIB) at 3.57 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max
58.18
Q3
25.77
Median
7.30
BIIB
3.57
Q1
3.01
Min
0.01
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Biogen (BIIB) at 1.94 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max
13.53
Q3
6.54
Median
3.25
BIIB
1.94
Q1
1.69
Min
-5.59
Loading chart…
Agilent (A) vs. Biogen (BIIB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Biogen (BIIB)
MetricABIIB
P/E Ratio (TTM)34.47107.51
P/S Ratio (TTM)6.683.57
P/B Ratio (MRQ)6.691.94
Free Cash Flow Yield (TTM)2.15%2.20%